Tag Archives: Back

ACC: Amarin rolls out more Vascepa heart benefits data to back label expansion

Amarin has rolled out new Vascepa data that could change the way doctors prevent heart disease. Monday, the company trumpeted more data showing its fish oil-derived Vascepa could significantly cut heart risks, and the drugmaker plans to add the benefits to the product’s label. Investigators of the REDUCE-IT trial previously found Vascepa could slash the risk of… Read More »

Primatene Mist Coming Back; Some Docs Concerned

Jason Shandell, president, Amphastar Pharmaceuticals Inc., Rancho Cucamonga, CA. Sandy Walsh, spokeswoman, FDA. FDA: “CDER Conversation: Safely Using the Newly Available OTC Asthma Inhaler Primatene Mist.” James Li, MD, PhD, professor of medicine, Mayo Clinic, Rochester, MN; former president, American Academy of Allergy, Asthma & Immunology. Dacia Morris, spokeswoman, American Thoracic Society, New York City.… Read More »